相关实验视频

Updated: Jan 14, 2026

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Published on: December 26, 2016

德尔塔-阿片类受体通过调节阿尔茨海默氏病病理中的C1q来改善微质诱导的突触损失

Yuan Xu¹, Ya Peng¹, Feng Zhi¹

¹Department of Neurosurgery, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, Jiangsu, China.

Brain, behavior, and immunity

|October 25, 2025

概括

德尔塔-阿片类受体 (DOR) 与C1q结合,抑制补充通路,并防止阿尔茨海默病的病理. 激活DOR可以减少神经炎症,并改善小鼠模型中的认知功能.

科学领域:

神经科学是一个神经科学.
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

阿尔茨海默病 (AD) 病理包括神经炎症和突触损失.
德尔塔阿片类受体 (DOR) 激活显示在AD中具有神经保护作用,但机制尚不清楚.
经典补充通路 (CCP) 有助于AD的发病.

研究的目的:

为了阐明阿尔茨海默病中DOR介导的神经保护的机制.
调查DOR与经典补充通路 (CCP) 组件C1q.之间的相互作用.
评估DOR激活在AD中的治疗潜力.

主要方法:

在体外和体内结合测定以确认DOR-C1q相互作用.
在APP/PS1转基因小鼠中使用DOR激动剂UFP-512.
评估CPC激活,微质细胞化,突触蛋白水平和认知功能.
过度表达微质DOR和评估神经元损伤模型.

主要成果:

观察到DOR和C1q之间的负相关性和直接结合.
在AD小鼠中,UFP-512治疗降低了C1q水平,增强了DOR-C1q结合,并抑制了CCP激活.
DOR激活改善了微质突触吞,防止了突触蛋白质的损失,并改善了认知.
过度表达微质DOR抑制了细胞和保护神经元免受损伤.

结论:

在神经退行症中,DOR在限制补充介导突触消除方面发挥着关键作用.
DOR-C1q相互作用是阿尔茨海默病中DOR介导的神经保护的关键机制.
准DOR代表了阿尔茨海默病的有希望的治疗策略.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在C1qq.德尔塔-阿片类受体受体微质细胞中的微质细胞突触剪裁是指突触剪裁.

更多相关视频

A High-content Assay for Monitoring AMPA Receptor Trafficking

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...

Opioid Receptors: Overview

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...